Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 806 results for "eisai"

Eisai receives positive CHMP opinion on new indication for anticancer agent...
Bio Spectrum Asia

ARENA PHARMACEUTICALS : Eisai Inc. and Arena Pharmaceuticals A...

/PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for BELVIQ XR (lorcaserin HCl) CIV extended-release 20 mg tablets. 4 Traders, 1 month ago
[x]  

87 images for eisai

DailyNews724.com, 2 weeks ago
pharmaphorum, 3 weeks ago
Yahoo! Singapore, 1 month ago
Minyanville, 1 month ago
Scrip Intelligence, 3 weeks ago
BioSpace, 1 month ago
Nikkei Asian Review, 1 month ago
Bio Spectrum Asia, 1 month ago
BioSpace, 1 month ago
Pharma Letter, 1 month ago

Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies

Japan's Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer's disease. The investigational oral beta-secretase cleaving ...
 Reuters2 weeks ago Arena Pharma's chronic weight management drug, Belviq XR gets US FDA approval  PharmaBiz1 month ago FDA approves Eisai's Belviq XR for chronic weight management  Pharmaceutical Technology1 month ago US FDA approves once-daily Belviq XR  Pharma Letter1 month ago
Pharmafile

Eisai's antiobesity agent Venespri receives Mexican approval

Eisai Co., Ltd. announced that its pharmaceutical sales subsidiary in Mexico, Eisai Laboratorios, S. de R.L. de C.V. has received approval for the antiobesity agent Venespri (lorcaserin hydrochloride, US brand name: Belviq, lorcaserin) as an adjunct ...
 PharmaBiz1 month ago Eisai introduces in-house developed anticancer agent Lenvima in Mexico  PharmaBiz1 month ago Eisai launches cancer drug Lenvatinib in Mexico  Pharmafile1 month ago Eisai Launches In-House Developed Novel Anticancer Agent Lenvima In Mexico  FirstWord Pharma1 month ago
Ecancer Medicalscience

EMA CHMP receives positive opinion for Eisai's combination treatment for RCC

Japanese-based Eisai has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on lenvatinib mesylate in combination with everolimus, to treat adult patients with advanced renal ...
 Pharmaceutical Technology1 month ago Lenvatinib and everolimus approved as combination therapy by CHMP  Ecancer Medicalscience1 month ago Pending EC decision: Kisplyx, lenvatinib, Opinion date: 21-Jul-2016  European Medicines Agency1 month ago
Investing.com

12 Stocks Moving In Thursday's Pre-Market Session

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) rose 8.8 percent to $1.74 in pre-market trading. Eisai and Arena Pharma reported the regulatory approval of VENESPRI in Mexico. Cree, Inc. (NASDAQ: CREE ) rose 7.7 percent to $27.00 in the ...
 Benzinga.com1 month ago DIA concludes two-day conference on pharmacovigilance in Mumbai  Express Pharma1 month ago Arena Pharmaceuticals Stock: Gaining On Drug Approval  Investing.com1 month ago Pharmalot, Pharmalittle: Next UK prime minister wants to shield pharma from takeovers  StatNews.com1 month ago
WorldNetDaily

BRIEF-R&I affirms Eisais rating at "A+" and stable outlook

July 8 Eisai Co Ltd : * Says rating and Investment Information, Inc. (R&I) affirmed the rating on Eisai at "A+" * Rating outlook stable Source text in Japanese: goo.gl/s91Vyf Further company coverage: (Beijing Headline News) ...
 Reuters UK1 month ago Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day  WorldNetDaily1 month ago EISAI : Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day  4 Traders1 month ago Eisai Inc. Highlights Its Strong Pipeline And Innovative Approach To R&D At Company's U.S. Scientific Day  BioSpace1 month ago
[x]  
MyNewsDesk

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Review, H1 2016 Featuring AskAt, Eisai, Eli Lilly and Company, Kaken Pharmaceutical & Ono Pharmaceutical - Research and Markets

Research and Markets has announced the addition of the "Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2016" report to their offering. Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or ...
 4 Traders1 month ago Global Epilepsy Drugs Market to Grow 4.45% - Social Stigma Associated with Epilepsy - Key Vendors are Eisai, GSK, Pfizer & UCB - Research and Markets  4 Traders1 month ago PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023 - Research and …  Yahoo! Finance1 month ago Global Epilepsy Drugs Sales Market Report 2021 Elite Market Features, Premium Strengths, Benefits, Analysis & Technical Developments  Before It's News1 month ago
[x]  
BioSpace

New Consensus Statement, Co-Sponsored by Eisai, is First to Address Role of Neurologist in Transitioning Pediatric Patients into the Adult Healthcare System

/PRNewswire/ -- The Child Neurology Foundation (CNF) announced today that a consensus statement addressing the role of the neurologist in transitioning children to the adult healthcare system has been published in the July 27, 2016 online edition of ...
 BioSpace1 month ago
[x]  
BioSpace

Eisai doses first patient in phase 1b/2 clinical trial of eribulin in combination with PEGPH20

The first patient has been dosed in a clinical trial to explore whether or not Eisai's eribulin in combination with Halozyme Therapeutics PEGPH20 can improve overall response rate (ORR) in women with advanced breast cancer. The collaborative phase ...
 Pharmaceutical Business Review1 month ago Halozyme and Eisai begin Phase Ib/II breast cancer trial of PEGPH20 and eribulin  Drug Development Technology1 month ago Halozyme Therapeutics : Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20  4 Traders1 month ago Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20  PressReleasePoint1 month ago
[x]  
CPhI.cn

Eisai chief pledges to subsidize thyroid cancer drug in CDF fight

The head of Eisai in Europe has pledged to subsidize the cost of thyroid cancer drug
 Pharma Letter1 month ago Eisai calls for immediate solution to CDF black hole  CPhI.cn1 month ago Patients denied thyroid cancer drug in England  pharmaphorum1 month ago Anger at exclusion of Eisai's Lenvima from Cancer Drugs Fund in England  Pharma Letter1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less